HSP27 inhibitor J2 (Synonyms: J2) |
| Catalog No.GC38503 |
HSP27 inhibitor J2(J2)은 HSP27의 일종의 억제제로 비정상적인 HSP27 이중체 형성을 유도하고 HSP27 macropolymer 생산을 억제한다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2133499-85-9
Sample solution is provided at 25 µL, 10mM.
HSP27 inhibitor J2(J2)은 HSP27의 일종의 억제제로 비정상적인 HSP27 이중체 형성을 유도하고 HSP27 macropolymer 생산을 억제한다.
J2(10 µM J2; 12 시간)은 HSP27을 높게 표현하는 폐암세포에서 더 강한 HSP27 교차 연결 활동을 보이며 상대적으로 낮은 세포 독성을 보였다[4].
J2(15 mg/kg; 복강 주입; 방사선 투여 후 14일 동안 홀수일에) 처리는 폐조직 내 면역세포 침투를 현저하게 억제했다. J2 처리된 쥐는 방사선 유발 호흡 곤란을 반전시켰습니다. J2는 쥐에서 IR 유발 폐섬유화를 억제했다[5-6].
References:
[1]. Hwang SY, Kwak SY, et,al. Synthesis and biological effect of chrom-4-one derivatives as functional inhibitors of heat shock protein 27. Eur J Med Chem. 2017 Oct 20;139:892-900. doi: 10.1016/j.ejmech.2017.08.065. Epub 2017 Sep 1. PMID: 28869891.
[2]. Garrido C, Bruey JM, et,al. HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J. 1999 Nov;13(14):2061-70. doi: 10.1096/fasebj.13.14.2061. PMID: 10544189.
[3]. Younghwa Na, et al. Methods for treating pulmonary fibrosis using chromenone derivatives.
[4]. Choi B, Choi SK, et,al. Sensitization of lung cancer cells by altered dimerization of HSP27. Oncotarget. 2017 Oct 31;8(62):105372-105382. doi: 10.18632/oncotarget.22192. PMID: 29285257; PMCID: PMC5739644.
[5]. Kim JY, An YM, et,al. HSP27 inhibitor attenuates radiation-induced pulmonary inflammation. Sci Rep. 2018 Mar 8;8(1):4189. doi: 10.1038/s41598-018-22635-9. PMID: 29520071; PMCID: PMC5843649.
[6]. Kim JY, Jeon S, et,al. The Hsp27-Mediated IkBα-NFκB Signaling Axis Promotes Radiation-Induced Lung Fibrosis. Clin Cancer Res. 2019 Sep 1;25(17):5364-5375. doi: 10.1158/1078-0432.CCR-18-3900. Epub 2019 May 24. PMID: 31126962.
| 세포 실험 [1]: | |
세포 라인 | NCI-H460세포 |
제조 방법 | 세포는 10µM의 J2로 12시간 동안 처리되었습니다. |
반응 조건 | 10 µM J2;12 시간 동안 |
응용 분야 | J2는 HSP27을 높게 표현하는 폐암세포에서 더 강한 HSP27 교차 연결 활동을 보였습니다. |
| 동물 실험 [2]: | |
동물 모형 | 수컷 C57BL/6 쥐 |
제조 방법 | 쥐는 좌측 폐에 단일 분량으로 75 Gy의 단일 용량에 노출되었고 방사선 투여 후 홀수일에 15 mg/kg의 J2를 복강 내 투여했습니다. |
제형 | 15 mg/kg; 복강 주입; 방사선 후 홀수일에, 14일간 |
응용 분야 | J2 치료는 폐조직 내 면역세포 침투를 현저하게 억제했습니다. |
참고문헌: [1]. Choi B, Choi SK, et,al. Sensitization of lung cancer cells by altered dimerization of HSP27. Oncotarget. 2017 Oct 31;8(62):105372-105382. doi: 10.18632/oncotarget.22192. PMID: 29285257; PMCID: PMC5739644.[2]. Kim JY, An YM, et,al. HSP27 inhibitor attenuates radiation-induced pulmonary inflammation. Sci Rep. 2018 Mar 8;8(1):4189. doi: 10.1038/s41598-018-22635-9. PMID: 29520071; PMCID: PMC5843649. | |
| Cas No. | 2133499-85-9 | SDF | |
| Synonyms | J2 | ||
| Canonical SMILES | O=C1C=C(C)OC2=C1C(O)=CC(OCC3SC3)=C2 | ||
| Formula | C13H12O4S | M.Wt | 264.3 |
| Solubility | DMSO: 25 mg/mL (94.59 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7836 mL | 18.9179 mL | 37.8358 mL |
| 5 mM | 756.7 μL | 3.7836 mL | 7.5672 mL |
| 10 mM | 378.4 μL | 1.8918 mL | 3.7836 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *